The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC
1 other identifier
observational
102
0 countries
N/A
Brief Summary
- 1.To evaluate the clinical utility of plasma circRNAs (hsa\_circ\_0004001) as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders.
- 2.To study the relation of circRNAs (hsa\_circ\_0004001) to HCC staging.
- 3.To compare between circRNAs (hsa\_circ\_0004001) and the routine marker (AFP) as biomarkers for HCC diagnosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2023
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 12, 2023
CompletedFirst Posted
Study publicly available on registry
September 21, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2025
CompletedOctober 4, 2023
September 1, 2023
1.1 years
September 12, 2023
October 1, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
(1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders
1. To evaluate the clinical utility of plasma circRNAs (hsa\_circ\_0004001) by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders 2. To study the relation of circRNAs (hsa\_circ\_0004001) to HCC staging. 3. To compare between circRNAs (hsa\_circ\_0004001) and the routine marker (AFP) as biomarkers for HCC diagnosis
baseline
Study Arms (3)
group 1
healthy control
group 2
patient with hepatic cell carcinoma
group 3
patient with non malignant liver diseased
Eligibility Criteria
(102 )individuals aged (18 years to 80years), did not receive any chemotherapy or surgical treatment The study will be carried out on patients who will be admitted to gastroenterology department at Assiut University hospital, and will be conducted at clinical pathology department, Assiut University Hospital, Faculty of medicine, Assiut University
You may qualify if:
- group one patients early diagnosed as HCC
- group two patient diagnosed with chronic non-malignant liver disease 3 group three healthy control group
You may not qualify if:
- Patients with any other type of malignant or benign tumors should be excluded from our study.
- History of chemotherapy or surgical treatment of cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- msc of clinical batology
Study Record Dates
First Submitted
September 12, 2023
First Posted
September 21, 2023
Study Start
November 1, 2023
Primary Completion
December 1, 2024
Study Completion
February 1, 2025
Last Updated
October 4, 2023
Record last verified: 2023-09